WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999007387) CHROMIUM/BIOTIN TREATMENT OF TYPE II DIABETES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1999/007387 International Application No.: PCT/US1998/016103
Publication Date: 18.02.1999 International Filing Date: 31.07.1998
Chapter 2 Demand Filed: 03.03.1999
IPC:
A61K 31/415 (2006.01) ,A61K 31/44 (2006.01) ,A61K 33/24 (2006.01)
Applicants: NUTRITION 21[US/US]; Suite 335 1010 Turquoise Street San Diego, CA 92109, US
Inventors: MCCARTY, Mark, F.; US
Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, LLP 16th floor 620 Newport Center Drive Newport Beach, CA 92660, US
Priority Data:
08/908,81908.08.1997US
09/110,51106.07.1998US
Title (EN) CHROMIUM/BIOTIN TREATMENT OF TYPE II DIABETES
(FR) TRAITEMENT AU CHROME/BIOTINE DU DIABETE DE TYPE II
Abstract:
(EN) A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 $g(m)g of chromium and between 25 $g(m)g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.
(FR) Une méthode de traitement du diabète de type II par administration à un individu affecté d'une combinaison de tripicolinate chromique et de biotine. Les deux composés sont administrés par voie orale ou parentérale selon des dosages quotidiens prévoyants de 50 à 1000 $g(m)g de chrome et de 25 $g(m) à 200 mg de biotine, les doses du chrome et de la biotine étant sélectionnées ensemble afin d'obtenir un effet supérieur à un effet additif.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)